Actinogen receives positive scientific advice from EMA
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Actinogen Medical Limited has announced that it received positive scientific advice from the European Medicines Agency regarding its Alzheimer's disease program, aligning with previous guidance from the FDA. The advice outlines a clear pathway to marketing approval, including the design of an additional pivotal clinical trial and the necessary studies for the drug Xanamem. The CEO expressed satisfaction with the EMA's guidance, which supports their streamlined development plans for Xanamem in Alzheimer's disease. The CMO highlighted the potential for groundbreaking trial results that could significantly impact the treatment of Alzheimer's disease.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Actinogen Medical Limited on 6ix
Earlier from Actinogen Medical
- Correction-March2026 quarterly activity report & Appendix 4C
- Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
- ACW XanaMIA Alzheimers open label trial commences
- ACW successfully completes $16.8m Placement and SPP
- ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
Later from Actinogen Medical
- Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program
- ACW third positive XanaMIA trial data committee review
- Xanamem depression trial published in British J Psychiatry
- June 2026 Quarterly activity report & Appendix 4C
- ACW Appendix 4E and 2026 annual report
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical